Bruce G. Hafty, MD Appointed Interim Director of the Rutgers Cancer Institute
January 14, 2016
I am pleased to announce the appointment of Bruce G. Haffty, MD, to serve as Interim Director of the Rutgers Cancer Institute of New Jersey. Dr. Haffty will officially assume this position upon Dr. Robert DiPaola’s departure on April 1, 2016.
Dr. Haffty currently serves as Professor and Chair of Radiation Oncology at Robert Wood Johnson Medical School, New Jersey Medical School, and the Cancer Institute of New Jersey where he is also Associate Director. He joined the Cancer Institute of New Jersey in 2005, after spending the majority of his career at Yale. He received his MD from the Yale University School of Medicine; his MS from the Worcester Polytechnic Institute; and his BS from the University of Massachusetts, Amherst.
Consistently ranked as one of the nation’s leading physicians by Best Doctors in America, Ladies Home Journal, Good Housekeeping, America’s Top Doctors, Top Doctors for Cancer, and Top Doctors in New York and New Jersey, Dr. Haffty is internationally recognized for his expertise in breast, and head and neck cancers. He has had numerous research grants related to clinical and translational research in radiation oncology and has mentored many medical students, house staff, and junior faculty in research projects. He was instrumental in launching the only residency programs in New Jersey for radiation oncology and medical physics.
Dr. Haffty’s clinical and laboratory research focuses on novel methods of delivering radiation and novel molecular targets to enhance the effects of radiation. A nationally recognized leader in radiation oncology, he has served as the president of the American Board of Radiology, the American Society for Radiation Oncology (ASTRO), and the American Radium Society, and as chair of the Residency Review Committee in Radiation Oncology. He has authored or co-authored of more than 300 peer-reviewed publications, multiple book chapters, and editorials; and was the editor of the comprehensive Handbook of Radiation Oncology. In addition to serving on numerous editorial boards, Dr. Haffty is presently an associate editor of the Journal of Clinical Oncology and serves on the board of directors of ASTRO and the Radiological Society of North America.
During this transition period, Dr. Haffty’s top priority will be to support the continued excellence of the clinical, research, educational, and prevention missions of the Institute.
I am also pleased to announce that Dr. Sherine Gabriel, Dean of Robert Wood Johnson Medical School, has graciously agreed to chair the search committee for a permanent director. We will launch the national search for a new director by the end of the month.
Please join me in extending congratulations and gratitude to Bruce and wishing him success in this new and important role for the Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, and the university.
Brian L. Strom, MD, MPH
Chancellor, Rutgers Biomedical and Health Sciences
Executive Vice President for Health Affairs